148 related articles for article (PubMed ID: 37834269)
1. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.
Luo L; Sun X; Yang Y; Xia L; Wang S; Fu Y; Zhu Y; Xu S; Zhu W
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834269
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
[TBL] [Abstract][Full Text] [Related]
3. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
[TBL] [Abstract][Full Text] [Related]
5. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
6. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
[TBL] [Abstract][Full Text] [Related]
9. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
[TBL] [Abstract][Full Text] [Related]
10. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Aggarwal S; John S; Sapra L; Sharma SC; Das SN
Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
[TBL] [Abstract][Full Text] [Related]
11. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Fluorine-18 (
Altine B; Gai Y; Han N; Jiang Y; Ji H; Fang H; Niyonkuru A; Bakari KH; Rajab Arnous MM; Liu Q; Zhang Y; Lan X
Mol Pharm; 2019 Nov; 16(11):4563-4571. PubMed ID: 31553879
[TBL] [Abstract][Full Text] [Related]
13. Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells.
Omeljaniuk WJ; Krętowski R; Ratajczak-Wrona W; Jabłońska E; Cechowska-Pasko M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768941
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1
Yang J; Liu Y; Lan S; Yu S; Ma X; Luo D; Shan H; Zhong X; Yan G; Li R
J Med Chem; 2022 Oct; 65(19):12781-12801. PubMed ID: 36191148
[TBL] [Abstract][Full Text] [Related]
18. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
20. The effects of PKI-402 on breast tumor models' radiosensitivity via dual inhibition of PI3K/mTOR.
Gasimli R; Kayabasi C; Ozmen Yelken B; Asik A; Sogutlu F; Celebi C; Yilmaz Susluer S; Kamer S; Biray Avci C; Haydaroglu A; Gunduz C
Int J Radiat Biol; 2023; 99(12):1961-1970. PubMed ID: 37389464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]